Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas-Reference-Cited by-同舟云学术

Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas

Published:2017-09-04 Issue:1 Volume:65 Page:e26719
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Spurny Christian¹,Kailayangiri Sareetha¹,Jamitzky Silke¹,Altvater Bianca¹,Wardelmann Eva²,Dirksen Uta¹^ORCID,Hardes Jendrik³,Hartmann Wolfgang²,Rossig Claudia¹⁴^ORCID

Affiliation:

1. Department of Pediatric Hematology and Oncology; University Children's Hospital Muenster; Muenster Germany

2. Gerhard Domagk Institute of Pathology; University of Muenster; Muenster Germany

3. Department of Orthopedic Surgery; University Hospital Muenster; Muenster Germany

4. Cells-in-Motion Cluster of Excellence (EXC 1003-CiM); University of Muenster; Muenster Germany

Funder

Löwenkinder® Verein zur Unterstützung krebskranker Kinder e.V.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference61 articles.

1. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future;Chen;J Clin Invest,2015

2. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition;Hegde;Clin Cancer Res,2016

3. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion;Dong;Nat Med,1999

4. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired;Ahmadzadeh;Blood,2009

5. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients;Fourcade;J Immunol,2009

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas;International Journal of Molecular Sciences;2023-05-05

2. Designing temporal- and spatial-control multifunctional nanoformulations for synergistic photodynamic–enhanced tumour immunotherapy;Nano Today;2023-04

3. The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma;Clinical Cancer Research;2023-03-09

4. Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma;Cancers;2022-12-30

5. The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies;Cancers;2022-04-27